Barb O'Bryen

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM 116367

Requestor's Name: Rebecca Cook

Serial Number: 09/784,618

Date: 3/1/04

Phone: 571 272 0571 ~~308-47~~ RC 4C70

Art Unit: 1614

MEJ

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevent citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevent claim(s).

Please search method of treating any cancer, malignancy etc (using MeSH terms) w/ compound of claim 12

Thanks
Rebecca

Rush Search Approved
TK Page
SPE, AU 1625

STAFF USE ONLY

Date completed:	3-15-04	**Search Site**		**Vendors**	
Searcher:	PAB		STIC		IG
Terminal time:	10		CM-1	248	STN
Elapsed time:	map 20		Pre-S		Dialog
CPU time:		**Type of Search**			APS
Total time:			N.A. Sequence		Geninfo
Number of Searches:			A.A. Sequence		SDC
Number of Databases:		1	Structure		DARC/Questel
			Bibliographic		Other

PTO-1590 (9-90)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 116367

TO: Rebecca Cook
Location: rem/4a65/4c70
Art Unit: 1614
Monday, March 15, 2004

Case Serial Number: 09/784618

From: Barb O'Bryen
Location: Biotech-Chem Library
Remsen E01A69
Phone: 571-272-2518

barbara.obryen@uspto.gov

Search Notes

RUSH

9-10. (Cancelled).

11. (Cancelled) A process for the production of a pharmaceutical preparation according to claim 8, characterized in that the compound according to formula (I) is mixed with the pharmaceutically compatible inert carrier or diluent.

12. (Currently Amended) A method of treating cancerous disease sensitive to ~~the preparation of claim 1~~ a compound of general formula (I)



(I)

wherein R_1 and R_2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.,

comprising administering ~~the preparation of claim 1~~ a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one of said compounds to a human being or a mammal in an amount effective to treat said cancerous disease.

13. (Previously Added) The method of claim 12, wherein said cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.

14. (Cancelled).

15. (Previously Added) The method according to claim 12, wherein said cancerous disease is selected from testicular tumors, ovarian carcinomas, bladder carcinomas, colonic carcinomas,

=> fil reg; d stat que l3; fil capl; d que nos 19; fil uspatf; d que nos l15; fil biosis toxcenter; d que nos l18
FILE 'REGISTRY' ENTERED AT 16:42:49 ON 15 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAR 2004 HIGHEST RN 663151-59-5
DICTIONARY FILE UPDATES: 14 MAR 2004 HIGHEST RN 663151-59-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L1 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 9
NSPEC IS RC AT 11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

3 nodes 9 & 11 are ring or chain

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L3 19 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 84 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 16:42:49 ON 15 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 14 Mar 2004 (20040314/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L1	STR	
L3	19	SEA FILE=REGISTRY SSS FUL L1
L5	44	SEA FILE=CAPLUS ABB=ON L3
L6	299833	SEA FILE=CAPLUS ABB=ON NEOPLASM#/CW
L7	94397	SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS/CT
L8	130802	SEA FILE=CAPLUS ABB=ON ?CARCINOMA?/BI
L9	8	SEA FILE=CAPLUS ABB=ON L5 AND (L6 OR L7 OR L8)

FILE 'USPATFULL' ENTERED AT 16:42:49 ON 15 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 11 Mar 2004 (20040311/PD)
FILE LAST UPDATED: 11 Mar 2004 (20040311/ED)
HIGHEST GRANTED PATENT NUMBER: US6704933
HIGHEST APPLICATION PUBLICATION NUMBER: US2004049824
CA INDEXING IS CURRENT THROUGH 11 Mar 2004 (20040311/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 11 Mar 2004 (20040311/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
L1              STR
L3           19 SEA FILE=REGISTRY SSS FUL L1
L13           8 SEA FILE=USPATFULL ABB=ON  L3
L14       69645 SEA FILE=USPATFULL ABB=ON  424/NCL
L15           2 SEA FILE=USPATFULL ABB=ON  L13 AND L14


FILE 'BIOSIS' ENTERED AT 16:42:49 ON 15 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'TOXCENTER' ENTERED AT 16:42:49 ON 15 MAR 2004
COPYRIGHT (C) 2004 ACS


L1              STR
L3           19 SEA FILE=REGISTRY SSS FUL L1
L16           9 SEA L3
L17     2288711 SEA ?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?CARCINOM?
L18           8 SEA L16 AND L17


=> dup rem l9,l15,l18
FILE 'CAPLUS' ENTERED AT 16:42:54 ON 15 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:42:54 ON 15 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:42:54 ON 15 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'TOXCENTER' ENTERED AT 16:42:54 ON 15 MAR 2004
COPYRIGHT (C) 2004 ACS
PROCESSING COMPLETED FOR L9
PROCESSING COMPLETED FOR L15
PROCESSING COMPLETED FOR L18
L23          10 DUP REM L9 L15 L18 (8 DUPLICATES REMOVED)
                ANSWERS '1-8' FROM FILE CAPLUS
                ANSWER '9' FROM FILE USPATFULL
                ANSWER '10' FROM FILE BIOSIS

=> d ibib ed abs hitstr 1-9; d iall 10

L23  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2004:157470  CAPLUS
TITLE:                    Treatment of cancer and autoimmune disease by a
                          pharmaceutical preparation containing palladium
                          complex compounds and other immunosuppressive agents
                          or cytostatic agents
INVENTOR(S):              Amtmann, Eberhard; Friebolin, Wolfgang; Schilling,
                          Gerhard
PATENT ASSIGNEE(S):       Deutsches Krebsforschungszentrum Stiftung Des
                          Oeffentlichen Rechts, Germany; Ruprecht-Karls-
                          Universitaet Heidelberg
SOURCE:                   Eur. Pat. Appl., 18 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
```

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1391221	A1	20040225	EP 2002-18922	20020823
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2004018043	A1	20040304	WO 2003-EP9247	20030820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2002-18922 A 20020823
ED Entered STN: 26 Feb 2004
AB The invention discloses pharmaceutical prepns. contg. palladium complexes and the use thereof for treating cancerous and autoimmune diseases. The pharmaceutical prepn. contains at least one compd. of general formula Pd(S2COR)2 [(un)substituted, (un)branched C1-30 alkyl or C2-30 alkyl alkenyl; (un)substituted mono- or polycyclic C3-30 alkyl or C4-30 alkenyl; (un)substituted mono- or polycyclic arom. residue].
IT INDEXING IN PROGRESS
IT **19965-15-2 63374-82-3**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(treatment of cancer and autoimmune disease by a pharmaceutical prepn. contg. palladium complex compds. and other immunosuppressive or cytostatic agents)
RN 19965-15-2 CAPLUS
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)- (9CI) (CA INDEX NAME)



RN 63374-82-3 CAPLUS
CN Platinum, bis[O-(1-methylethyl) carbonodithioato-S,S']-, (SP-4-1)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2003:971254 CAPLUS
DOCUMENT NUMBER: 140:8767

TITLE: Radiolabelled thioplatin, compositions thereof and methods of cancer treatment
INVENTOR(S): Aranoff, Shraga D.; Schwartzberg, Jack; Order, Stanley E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 3 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003228253	A1	20031211	US 2002-184543	20020628
PRIORITY APPLN. INFO.:			US 2002-386592P P	20020606

ED Entered STN: 12 Dec 2003
AB Radioactive platinum compds., such as thioplatin, formulated with a suitable carrier, may be used for treating cancer.
IT **19965-15-2D**, Thioplatin, radiolabeled
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(radioactive platinum compds. for treating cancer)
RN 19965-15-2 CAPLUS
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



L23 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2003:969412 CAPLUS
DOCUMENT NUMBER: 140:730
TITLE: Human genes deregulated in drug-resistant tumor cells in response to cytotoxic drugs and methods for diagnosis and treatment of cancer
INVENTOR(S): Wittig, Rainer; Poustka, Annemarie; Mollenhauer, Jan; Schadendorf, Dirk
PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1369482	A1	20031210	EP 2002-12705	20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-12705	20020607

ED Entered STN: 12 Dec 2003
AB The present invention relates to the identification and use of target genes for the detection and treatment of drug-resistant tumor cells. The nucleic acids of the present invention exhibit a deregulated phenotype when the tumor cells are subjected to cytostatic drugs, i.e.. they are expressed in a higher or lower amt. as compared to parental drug-sensitive

cancer cells. Thus, they can be used as a diagnostic and pharmaceutical tool to render drug-resistant cells drug-sensitive. In addn., the present invention includes the polypeptides encoded by the resp. nucleic acids, expression vectors harboring the nucleic acids, host cells for expression and methods for the diagnosis and treatment of drug-resistant tumor cells.

IT **19965-15-2**, Thioplatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human genes deregulated in drug-resistant tumor cells in response to cytotoxic drugs and methods for diagnosis and treatment of cancer)

RN 19965-15-2 CAPLUS

CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:833884 CAPLUS
DOCUMENT NUMBER: 139:317425
TITLE: Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis
INVENTOR(S): Debatin, Klaus Michael; Fulda, Simone
PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1354952	A1	20031022	EP 2002-8199	20020417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1354953	A1	20031022	EP 2002-15499	20020712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2003086470	A2	20031023	WO 2003-EP4039	20030417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2002-8199 A 20020417
EP 2002-15499 A 20020712

ED Entered STN: 24 Oct 2003

AB The invention is directed to the use of Smac to sensitize different tumors

and self-reactive immune cells to various pro-apoptotic stimuli, in that the cells subsequently undergo apoptosis. Therefore, Smac can be used as a compd. for the manuf. of a medicament for the treatment of cancer and autoimmune diseases. Sensitization of the cells is achieved either by applying a cell-permeable form of Smac combined with known anticancer agents or by overexpression of the protein. It is an object of the invention to provide a new method in cancer and autoimmune disease therapy by using Smac agonists for apoptosis regulation. Thus, Smac agonists represent novel promising cancer and autoimmune disease therapeutics to potentiate the efficacy of cytotoxic therapies even in resistant tumors and immune cells. In particular, overexpression of full-length Smac protein potentiated TRAIL-induced apoptosis and also markedly increased apoptosis induced by anti-CD95 antibody or cytotoxic drugs in transfected SHEP neuroblastoma cells. The overexpression of Smac is shown to promote apoptosis through antagonizing the inhibition of XIAP of both distal and proximal events in the caspase cascade. The cytosolic Smac, with the deletion of transit peptide for mitochondria (N-terminal 55 AA), bypasses Bcl-2 inhibition in several cell types in response to different pro-apoptotic stimuli. The cell permeable Smac peptide (4 N-terminal IAP-interacting plus 3 addn. following residues linked to TAT transduction domain) can facilitate intracellular delivery of Smac peptide and sensitize several resistant cell lines with defects in apoptosis signaling for treatment with TRAIL or doxorubicin. Expression of a cytosolic active form of Smac or cell-permeable Smac peptides bypassed the Bcl-2 block, which prevented the release of Smac from mitochondria, and also sensitized resistant neuroblastoma or melanoma cells and patient-derived primary neuroblastoma cells ex vivo. Thus, Smac agonists represent novel promising cancer therapeutics to potentiate the efficacy of cytotoxic therapies. Smac peptides is shown to enhance the antitumor effect of TRAIL in glioblastoma in mouse glioblastoma model and induce eradication of tumors.

IT **19965-15-2**, Thioplatin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(therapeutic combination with SMAC peptide; Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis)

RN 19965-15-2 CAPLUS

CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2001:422765 CAPLUS

DOCUMENT NUMBER: 136:272726

TITLE: Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum

AUTHOR(S): Amtmann, Eberhard; Zoller, Margot; Wesch, Horst; Schilling, Gerhard

CORPORATE SOURCE: Department D0600, German Cancer Research Centre, Heidelberg, 69120, Germany

SOURCE: Cancer Chemotherapy and Pharmacology (2001), 47(6), 461-466
CODEN: CCPHDZ; ISSN: 0344-5704

PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 12 Jun 2001
AB Platinum complexes are essential tools for cancer treatment despite their toxic side effects. Here we describe a new platinum complex with sulfurs as complexing atoms (thioplatin). Purpose: To demonstrate that the antitumoral activity of a new sulfur-contg. platinum compd. (thioplatin) depends on a slightly acidic pH. Methods: Platinum uptake by tumor cells and interaction with DNA was detd. at slightly acidic or alk. pH. To demonstrate low in vivo toxicity the effects of thioplatin on body wt., blood urea nitrogen, white blood cell count and the histopathol. appearance of small intestines and kidneys were evaluated at doses that displayed antitumoral effects against human small-cell lung cancer and human colorectal cancer xenotransplants in nude mice. Results: The slightly acidic pH optimum of thioplatin was proven by the altered electrophoretic mobility of plasmid DNA, quantitation of the platinum content in the DNA of tumor cells and cytotoxicity studies. Thioplatin displayed antitumoral activity without severe side effects such as wt. loss, renal ischemia, destruction of villi in the small intestine or leukopenia as obsd. at comparable doses of cisplatin. Furthermore, probably due to its lipophilic nature, thioplatin was taken up readily even by cisplatin-resistant cells. In vivo studies with human tumor xenografts in nude mice showed a therapeutic index of thioplatin five to ten times higher than that of cisplatin.
IT **19965-15-2**, Thioplatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumoral activity of a sulfur-contg. platinum complex with acidic pH optimum)
RN 19965-15-2 CAPLUS
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2000:144715 CAPLUS
DOCUMENT NUMBER: 132:189657
TITLE: Medicament containing platinum complex compounds and its use
INVENTOR(S): Amtmann, Eberhard; Schilling, Gerhard
PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany; Ruprecht-Karls-Universitaet Heidelberg
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010543	A2	20000302	WO 1999-DE2656	19990825

WO 2000010543 A3 20000810
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341701	AA	20000302	CA 1999-2341701	19990825	
DE 19940407	A1	20000309	DE 1999-19940407	19990825	
AU 2000010286	A1	20000314	AU 2000-10286	19990825	
BR 9913321	A	20010515	BR 1999-13321	19990825	
EP 1107751	A2	20010620	EP 1999-953589	19990825	
EP 1107751	B1	20030604			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002523361	T2	20020730	JP 2000-565865	19990825	
AT 241975	E	20030615	AT 1999-953589	19990825	
NZ 509529	A	20030725	NZ 1999-509529	19990825	
PT 1107751	T	20031031	PT 1999-99953589	19990825	
US 2002004526	A1	20020110	US 2001-784618	20010215	
NO 2001000907	A	20010425	NO 2001-907	20010222	

PRIORITY APPLN. INFO.: DE 1998-19838547 A 19980825
WO 1999-DE2656 W 19990825

OTHER SOURCE(S): MARPAT 132:189657
ED Entered STN: 03 Mar 2000
GI



I

AB Pt carbonodithioate complexes (I; R1, R2 = C1-30 alkyl, C2-30 alkenyl, C3-30 cycloalkyl or polycyclic alkyl, C4-30 cycloalkenyl or polycyclic alkenyl, C6-30 aryl or polycyclic arom. residue, any of which may be substituted) are useful in medicaments for immunosuppressive therapy and noninvasive tumor therapy. Thus, cis-dichlorodiammineplatinum(II) reacted with K ethylxanthogenate to form I (R1 = R2 = Et) (II). II (10 mg/kg i.v.) was effective against human bronchial small-cell **carcinomas** in nude mice.

IT **19965-15-2P 52596-22-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor medicament contg. platinum complex compds.)

RN 19965-15-2 CAPLUS
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



RN 52596-22-2 CAPLUS

CN Platinum, bis(O-methyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-
(9CI) (CA INDEX NAME)



L23 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 1987:508004 CAPLUS
DOCUMENT NUMBER: 107:108004
TITLE: Synthesis and antitumor activity of cis-dichloroplatinum complexes coordinating nitrogen cyclic or sulfur compounds
AUTHOR(S): Osa, Tetsuo; Hino, Hiroaki; Fujieda, Shigeaki; Shiio, Tsuyoshi; Kono, Tetsuo
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1986), 34(9), 3563-72
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 19 Sep 1987
AB cis-PtClL2 (L = N cyclic compds. and S-contg. compds.) were prepd. through the reaction of K2PtCl4 with L in H2O or an interfacial layer between water and an org. solvent. The effect of substituents of pyridine derivs. on the prepn. of cis-PtCl2L2 depended greatly on their position. The coordination of 2-substituted pyridines required a long reaction time and the yields were low. That of 3- or 4-substituted pyridines proceeded smoothly in high yields. The complexes with dimethylpyridines or trimethylpyridines were obtained in low yields, but a Me group at the para position increased the coordination activity of pyridines. The reactivity of other N cyclic compds. depended greatly on their structures and no clear correlation between structure and reactivity was obsd. In some cases, polynuclear or unidentified complexes were formed. S contg. compds. reacted smoothly in high yields. Three cis-PtCl2L2 (L = 3-methylpyridine, quinoline and isoquinoline) and Pt4Cl5(OH)3L'.3H2O (L' = piperidine) had high antitumor activities against Sarcoma 180 ascites in female ICR/CRJ mice. The required Pt wt. of these effective complexes for antitumor activity was 23-94 mg/kg in mice compared with 5 mg/kg for cis-PtCl2(NH3)2.
IT **19965-15-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antitumor activity of)
RN 19965-15-2 CAPLUS
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-
(9CI) (CA INDEX NAME)



L23 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:120684 CAPLUS

DOCUMENT NUMBER: 140:187383
TITLE: Lipid-drug complexes in reversed liquid and liquid crystalline phases
INVENTOR(S): Anderson, David M.
PATENT ASSIGNEE(S): Lyotropic Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012680	A2	20040212	WO 2003-US24512	20030806

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-401011P P 20020806
ED Entered STN: 13 Feb 2004
AB A pharmaceutical is formulated to enable enhanced delivery across membrane barriers, permit solubilization, protect compds. from deactivation by thiol contg. compds. in the body, and allow retention of the drug during transport to a desired site of activity. The pharmaceutical includes a complex of two moieties where at least one is pharmaceutically active and is larger than a single atom in size, and the second moiety, when combined with a cationic or anionic counterion forms either a pharmaceutically acceptable anionic or cationic surfactant or a pharmaceutically acceptable salt that has an octanol water partition coeff. of greater than about 100. A compn. contained cisplatin in dimethylacetamide and Epikuron 105.
IT **19965-15-2**, Thioplatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid-drug complexes in reversed liq. and liq. cryst. phases)
RN 19965-15-2 CAPLUS
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



L23 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2002:8526 USPATFULL
TITLE: Medicament containing platinum complex compounds and the use thereof
INVENTOR(S): Amtmann, Eberhard, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
Schilling, Gerhard, Ladenburg, GERMANY, FEDERAL REPUBLIC OF

NUMBER KIND DATE

PATENT INFORMATION:	US 2002004526	A1	20020110
APPLICATION INFO.:	US 2001-784618	A1	20010215 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-DE2656, filed on 25 Aug 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19838547	19980825

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, ONE BEACON STREET, BOSTON, MA, 02108-3190
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical preparation containing at least one compound of general formula (I) ##STR1##

wherein R.sub.1 and R.sub.2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents. This invention also relates to the use of the pharmaceutical preparations for the immunosuppressive treatment and for the non-invasive treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **19965-15-2P 52596-22-2P**
(antitumor medicament contg. platinum complex compds.)
RN 19965-15-2 USPATFULL
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



RN 52596-22-2 USPATFULL
CN Platinum, bis(O-methyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-(9CI) (CA INDEX NAME)



L23 ANSWER 10 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:367409 BIOSIS

DOCUMENT NUMBER: PREV200200367409
TITLE: Thioplatin: A sulfur-containing platinum complex possessing greater activity in acidic pH, non-cross resistance with cisplatin and **antitumor** activity in vivo.
AUTHOR(S): Rowlinson-Busza, Gail [Reprint author]; Griffiths-Johnson, David [Reprint author]; Hadfield, Samantha [Reprint author]; Courtenay-Luck, Nigel [Reprint author]; Kelland, Lloyd R. [Reprint author]
CORPORATE SOURCE: St Georges Hospital Medical School, London, UK
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2002) Vol. 43, pp. 61. print.
Meeting Info.: 93rd Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA. April 06-10, 2002.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Jul 2002
Last Updated on STN: 29 Aug 2002
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - General 10060
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Biochemistry studies - Proteins, peptides and amino acids 10064
Biochemistry studies - Carbohydrates 10068
Pathology - Therapy 12512
Respiratory system - Physiology and biochemistry 16004
Respiratory system - Pathology 16006
Reproductive system - Physiology and biochemistry 16504
Reproductive system - Pathology 16506
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; **Tumor** Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
lung: respiratory system; ovary: reproductive system
INDEX TERMS: Diseases
non-small cell lung **cancer: neoplastic** disease, respiratory system disease
Carcinoma, Non-Small-Cell Lung (MeSH); Lung **Neoplasms** (MeSH)
INDEX TERMS: Diseases
ovarian **carcinoma: neoplastic** disease, reproductive system disease/female
Ovarian **Neoplasms** (MeSH); **Carcinoma** (MeSH)
INDEX TERMS: Chemicals & Biochemicals
DNA; P-glycoprotein; cisplatin: **antineoplastic** -drug; glutathione; hMLH1; oxaliplatin: **antineoplastic**-drug; thioplatin [bis-(O-ethyl dithiocarbamato)platinum (II)]: **antineoplastic** -drug
INDEX TERMS: Miscellaneous Descriptors
acidic pH; Meeting Abstract
ORGANISM: Classifier

Searched by Barb O'Bryen, STIC 571-272-2518

Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
NCI H460 cell line: human non-small cell lung **cancer** cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
REGISTRY NUMBER: 15663-27-1 (cisplatin)
70-18-8 (glutathione)
61825-94-3 (oxaliplatin)
19965-15-2 (THIOPLATIN)

=> fil reg; s 19965-15-2
FILE 'REGISTRY' ENTERED AT 16:43:29 ON 15 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAR 2004 HIGHEST RN 663151-59-5
DICTIONARY FILE UPDATES: 14 MAR 2004 HIGHEST RN 663151-59-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L24 1 19965-15-2
(19965-15-2/RN)

=> d ide

L24 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **19965-15-2** REGISTRY
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Carbonodithioic acid, O-ethyl ester, platinum complex
CN Platinum, bis(hydrogen dithiocarbonato)-, O,O-diethyl ester (8CI)
CN Platinum, bis(O-ethyl carbonodithioato-S,S')-, (SP-4-1)-
OTHER NAMES:

CN Bis(ethyl xanthato)platinum
CN Bis(O-ethyl dithiocarbonato)platinum
CN Thioplatin
DR 3444-55-1
MF C6 H10 O2 Pt S4
CI CCS
LC STN Files: BIOSIS, CA, CAOLD, CAPLUS, GMELIN*, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSRESEARCH, SYNTHLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



structure for Biosis Hit Registry #

28 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil cao; d que nos l22; fil hom
FILE 'CAOLD' ENTERED AT 16:43:40 ON 15 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L1 STR
L3 19 SEA FILE=REGISTRY SSS FUL L1
L20 2 SEA FILE=CAOLD ABB=ON L3
L21 17025 SEA FILE=CAOLD ABB=ON ?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLAS? OR ?CARCINOM?
L22 0 SEA FILE=CAOLD ABB=ON L20 AND L21

FILE 'HOME' ENTERED AT 16:43:40 ON 15 MAR 2004